Opill

What Opill does

Opill is a single-product consumer healthcare brand and the first FDA-approved over-the-counter daily oral contraceptive available in the United States, containing 0.075mg norgestrel as a progestin-only formulation that is 98% effective when used as directed. The product is sold in 1-month (28-day) and 3-month (84-day) packs, is estrogen-free, and has a 50-year clinical safety record underlying the active ingredient. It is positioned for people of reproductive age who can become pregnant, including those who cannot take estrogen-based contraceptives, with no prescription, doctor's appointment, or age restriction required. Opill is a registered trademark of Perrigo Company plc (NYSE: PRGO), a publicly traded Irish-domiciled consumer healthcare company; Perrigo owns and operates the brand as a wholly-owned subsidiary product line, and Opill is not an independent venture-backed entity.

The product is supported by a hybrid distribution model: direct-to-consumer e-commerce at opill.com with autoship subscriptions (3- and 6-month cycles at 5% savings), free shipping, HSA/FSA payment eligibility, and a $0 out-of-pocket pathway for CVS Caremark-covered members via the insurance Preventive Medications List. Retail distribution spans family planning aisles at major retailers across all 50 U.S. states, with additional availability through major online marketplaces. Shipping is handled via USPS in discreet packaging, with 24–48 hour dispatch and a 2-day delivery option. The technology stack is standard e-commerce infrastructure (Shopify storefront, PayPal, major credit cards, HSA/FSA), and the proprietary moat is regulatory rather than technological.

The business model combines one-time OTC pack sales with recurring subscription revenue, a Cost Assistance Program (CAP) for uninsured and underinsured consumers, a Refer-a-Friend program providing $5 credits per qualified referral, and a Donation Program managed with SIRUM that has distributed over 115,000 packs to healthcare clinics, nonprofit organizations, and advocacy groups serving underserved communities as of May 2025. Customer service is operated 8:00am–5:00pm EST, M–F, via a dedicated U.S. support line and email. Operating geographies are United States-only, and no separate revenue, headcount, or cap table is disclosed for the Opill brand because it is consolidated within Perrigo's public financial reporting.

Name

Opill

Legal name

Perrigo Company plc

Website

https://opill.com

Company type

Public

Founded year

2023

Operating status

Operating

Short description

Opill is the first FDA-approved over-the-counter daily oral contraceptive, offering a 0.075mg norgestrel progestin-only pill without prescription to individuals of reproductive age across the United States. It is a wholly-owned product brand of Perrigo Company plc (NYSE: PRGO).

Ownership category

akta.pro rank

Product category

Oral Contraceptives

NAICS

Health and Personal Care Retailers (456)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Fertility & Ovulation Products (OTC) (CRABAIAK)

Keywords

• Over-the-counter contraceptives
• Daily oral contraceptive pills
• Progestin-only birth control
• OTC reproductive health products
• Contraception subscription service

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D

Revenue model

1. Direct Product Sales: One-time purchase of Opill birth control pill packs (1-month supply or 3-month supply) through opill.com e-commerce platform and retail stores nationwide.
2. Subscription/Autoship Program: Recurring subscription model offering 3-month or 6-month auto-delivery options with 5% savings. Billing occurs approximately 14 days before current supply ends, ensuring continuous delivery. Customers can easily change, pause, or cancel subscriptions online.
3. Insurance Reimbursement: Some insurance plans such as CVS Caremark have added Opill to their Preventive Medications List, allowing eligible customers to purchase for $0 out-of-pocket without prescription. Company accepts receipt submission for reimbursement to insurance carriers.
4. FSA/HSA Payments: Opill is FSA/HSA eligible, allowing customers to use pre-tax flexible spending or health savings account funds for purchase, expanding payment flexibility.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Opill sells the first FDA-approved over-the-counter daily oral contraceptive pill in the United States, containing 0.075mg norgestrel (progestin-only, estrogen-free) and reported 98% effective when used as directed. The product is available without a prescription or age restriction through the company's direct-to-consumer website (opill.com) and across retailers in all 50 U.S. states. Supporting offerings include an autoship subscription service, a cost assistance program (CAP), a donation program for underserved communities, and a refer-a-friend rewards program.

Product overview

Opill® is a single-product pharmaceutical brand offering the first FDA-approved over-the-counter daily birth control pill in the US. The core product is Opill® (0.075mg norgestrel), a progestin-only oral contraceptive available in 1-month (28 tablets) and 3-month (84 tablets) packs, sold direct-to-consumer online and at retail stores nationwide without prescription. The product portfolio is supported by complementary services including an Autoship/Subscription program for convenient recurring delivery, a Cost Assistance Program (CAP) for financial assistance, a Donation Program for community distribution, and a Refer-a-Friend referral rewards program.

Differentiator

Problem solved

Functional benefit

Products and services

• Opill® Daily Oral Contraceptive (1-Month Pack) A 28-day supply of daily oral contraceptive tablets containing 0.075mg norgestrel (progestin-only, estrogen-free), reported 98% effective when used as directed. Sold without a prescription to consumers of reproductive age in the United States via opill.com and retail stores nationwide.
• Opill® Daily Oral Contraceptive (3-Month Pack) An 84-day supply of daily oral contraceptive tablets containing 0.075mg norgestrel (progestin-only, estrogen-free), 98% effective when used as directed. Sold without a prescription as a multi-month bulk option for ongoing daily contraception.
• Opill® Autoship/Subscription Service A recurring auto-delivery subscription offering 3- or 6-month Opill supply cycles at 5% savings, with automatic billing approximately 14 days before current supply ends and online management of pause, change, or cancellation.
• Opill® Cost Assistance Program (CAP) A financial assistance program that helps individuals with financial or insurance coverage limitations afford Opill. Applicants must meet specific criteria and apply through opillcap.com.
• Opill® Donation Program A program that provides free Opill to organizations promoting reproductive health, well-being, and education for individuals who can become pregnant, supporting healthcare clinics, nonprofits, and advocacy groups serving underserved communities via SIRUM-managed applications.
• Opill® Refer-a-Friend Program A referral reward program offering $5 credits (O-Points) to existing customers for each qualified first-time purchase by a referred friend, with the referred customer also receiving a $5 credit; credits expire after one year and are redeemable at opill.com.

Quantifiable outcome

• 98% effective when used as directed
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Healthcare ClinicscoreChannel Partner/ Reseller/ DistributorHealthcare clinics receive donated Opill product through the Opill Donation Program to distribute free of charge to underserved communities and individuals in need of contraception access.
• Nonprofit OrganizationscoreChannel Partner/ Reseller/ DistributorNonprofit organizations focused on reproductive health, well-being, and education partner with Opill to receive free product donations for distribution to communities in need. Over 115,000 packs donated to date.
• Advocacy GroupscoreGTM or Marketing PartnerAdvocacy groups supporting reproductive health access receive Opill donations through the program, promoting shared commitment to enhancing reproductive health education and contraception accessibility.
• United States Postal Service (USPS)minorOthersUSPS is the trusted shipping carrier for Opill orders, handling domestic package delivery with tracking and 2-day delivery options available.
• CVS CaremarkcoreChannel Partner/ Reseller/ DistributorCVS Caremark insurance plans have added Opill to their Preventive Medications List, allowing eligible Caremark customers to purchase Opill for $0 out-of-pocket without a prescription.
• SIRUMcoreImplementation/ SI/ Consulting PartnerSIRUM (Sustainable International Relief for Underprivileged People) partners with Opill to manage the donation program application process, enabling organizations to apply for and receive donated Opill product.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• The Pill Club: Online birth control prescription and delivery service. Closely comparable DTC contraceptive distribution model that eliminates the need for an in-person clinic visit, addressing the same access barriers Opill targets.
• Nurx: Telehealth platform offering prescription birth control and other women's health products direct-to-consumer. Direct overlap with Opill in delivering contraception without an in-person physician visit, though operating on the prescription side.
• Wisp: Telehealth women's health brand offering birth control, UTI treatment, and reproductive care online. Competes with Opill for the same DTC contraceptive consumer with similar convenience-and-discretion messaging.
• Hims & Hers Health: Publicly traded direct-to-consumer telehealth platform with a women's health vertical (Hers) that offers prescription birth control. Comparable DTC consumer acquisition playbook and subscription model in reproductive health.

Emerging players

• Twentyeight Health: Telehealth reproductive and sexual health platform focused on birth control access, with particular emphasis on underserved and Medicaid populations. Comparable mission-driven DTC contraception delivery model.

Others

• Foundation Consumer Healthcare: OTC women's health brand owner of Plan B One-Step emergency contraception. Closest OTC women's health brand comparable in category dynamics, retail distribution, and consumer purchase behavior even though the product is emergency rather than daily contraception.

Broad incumbents

• Organon & Co. Publicly traded pharmaceutical company spun out of Merck with a focused women's health portfolio including several leading contraceptive brands. Most directly comparable incumbent given its strategic focus on reproductive health.
• Teva Pharmaceutical: Generic pharmaceutical leader with significant contraceptive and women's health generic offerings. A plausible OTC entrant given low-cost manufacturing capability and US retail relationships.
• Bayer (Women's Health / Contraceptive franchise): Global pharmaceutical company whose contraceptive franchise (Yaz, Mirena, Kyleena) dominates the prescription birth control market. Most relevant incumbent comparator given Bayer's likely interest in the OTC daily contraceptive category.
• Pfizer: Diversified pharma giant with a prescription contraceptive portfolio. A potential OTC entrant or acquirer in the OTC daily contraceptive space given regulatory capabilities and distribution scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/opill_otc
• Facebookfacebook.com/opillotc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opill